RGNX
RGNX clinical trials: REGENXBIO Inc.
Every trial on ClinicalTrials.gov where REGENXBIO Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 25
- Trials linked
- 18
- As lead sponsor
- 7
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RGNX on the catalyst calendar · RGNX registry changes
- Primary completion Oct 2028Sponsor estimateNo phase registeredNCT04597385Long-term Follow-Up for RGX-121REGENXBIO Inc. · Mucopolysaccharidosis IIActive, not recruitingRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 2/Phase 3NCT05693142AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)REGENXBIO Inc. · Duchenne Muscular DystrophyActive, not recruitingRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2026ActualNo phase registeredNCT05683379AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMDREGENXBIO Inc. · Duchenne Muscular DystrophyActive, not recruitingRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07652606Expanded Access to RGX-202REGENXBIO Inc.Temporarily not availableRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2028Sponsor estimatePhase 3NCT07236606RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)REGENXBIO Inc. · MPS IIActive, not recruitingRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimateNo phase registeredNCT06103487Long Term Follow-Up for RGX-111REGENXBIO Inc. · Mucopolysaccharidosis IEnrolling by invitationRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2029Sponsor estimateNo phase registeredNCT06491927Long Term Follow-up for RGX-202REGENXBIO Inc. · Duchenne Muscular DystrophyEnrolling by invitationRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2027Sponsor estimatePhase 1/Phase 2NCT03580083RGX-111 Gene Therapy in Patients With MPS IREGENXBIO Inc. · Mucopolysaccharidosis Type I (MPS I)SuspendedRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2023ActualPhase 1/Phase 2NCT04571970RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)REGENXBIO Inc. · Mucopolysaccharidosis Type II (MPS II)CompletedRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2023ActualPhase 2/Phase 3NCT03566043CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)REGENXBIO Inc. · Mucopolysaccharidosis Type II (MPS II)Active, not recruitingRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2020ActualPhase 1/Phase 2NCT02651675A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)REGENXBIO Inc. · Homozygous Familial Hypercholesterolemia (HoFH)TerminatedRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2019ActualPhase 1/Phase 2NCT03066258Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD TrialREGENXBIO Inc. · Neovascular Age-related Macular DegenerationCompletedRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2024Sponsor estimateNo phase registeredNCT04080050A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501REGENXBIO Inc. · Homozygous Familial Hypercholesterolemia (HoFH)Unknown statusRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2025Sponsor estimateNo phase registeredNCT04591834Mucopolysaccharidosis Type II ObservationalREGENXBIO Inc. · Mucopolysaccharidosis IIWithdrawnRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 22, 2022ActualNo phase registeredNCT03529786Mucopolysaccharidosis Type II Natural HistoryREGENXBIO Inc. · Mucopolysaccharidosis IICompletedRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2022Sponsor estimateNo phase registeredNCT04480476A Retrospective, Natural History Study in Children With CLN2REGENXBIO Inc. · Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)WithdrawnRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2023Sponsor estimateNo phase registeredNCT04462692An Observational Study in Children With CLN2 Batten DiseaseREGENXBIO Inc. · Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)WithdrawnRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2020ActualNo phase registeredNCT04148001Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) PatientsREGENXBIO Inc. · Homozygous Familial Hypercholesterolemia (HoFH)CompletedRGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2026ActualPhase 2NCT04514653RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)AbbVie · Neovascular Age-Related Macular Degeneration (nAMD)Active, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2026ActualPhase 2NCT04567550RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center...AbbVie · Diabetic Retinopathy (DR)CompletedABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2031Sponsor estimatePhase 2NCT05296447Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyAbbVie · Diabetic Retinopathy, DRActive, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2031Sponsor estimatePhase 2NCT05210803Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDAbbVie · Neovascular Age-Related Macular Degeneration (nAMD)Enrolling by invitationABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 3NCT05407636Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDAbbVie · AMDActive, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT04704921Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDAbbVie · AMDActive, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT06942520Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)Sierra Eye Associates · Diabetic Macular EdemaRecruitingRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner